Business WireQuinnova Pharmaceuticals Inc

Jarrett Jack can be used if Jose Calderon (hip) continues to be out.Utah Jazz : MIN, OKC, vs. DENCarlos Boozer, Deron Williams, Mehmet Okur, and Andrei Kirilenko are nice options Ronnie Brewer, Paul Millsap, and C.J Miles are options.Washington Wizards : MEM, vs OKC, vs. SAGilbert Arenas, Caron Butler, Antawn Jamison, and Brendan Haywood are the only ones I’d trust right now. Two Games Detroit Pistons : vs NY, vs CHIRodney Stuckey is the only legit option. Charlie Villanueva (foot) is struggling.Los Angeles Clippers : POR, vs PHIUse Chris Kaman, Baron Davis, and Marcus Camby Originally published at LestersLegends ..

NEWTOWN, Pa.(Business Wire)Quinnova Pharmaceuticals, Inc. announced today the launch of Neosalus, the firstnon-steroidal anti-inflammatory prescription topical foam product for thetreatment of various types of dermatoses including atopic dermatitis and handeczema. Neosalus, uniquely formulated with Quinnovas patented ProdermTechnology TM, provides skin barrier repair, protection, and moisturization. "To treat recalcitrant skin conditions such as atopic dermatitis and handeczema, a comprehensive and long term solution is required to address theunderlying issue of a compromised skin barrier while reducing inflammation,"said Dr Christopher N Hensby, Senior Vice President of QuinnovaPharmaceuticals. First and foremost, Neosalus helps to restore a dysfunctionalskin barrier by replenishing the lost lipids, thereby decreasing trans-epidermalwater loss (TEWL).

Furthermore, Neosalus functions as a protectant to reduce thepenetration of irritants from further exacerbating the itch and scratch cycle.Finally, Neosalus has anti-inflammatory ability that helps to reduce thefrequency and severity of flare-ups, thus making it a steroid sparing andcomplementary treatment to other concomitant treatments. In addition to the therapeutic benefits of Neosalus, patients will likelyappreciate the cosmetic elegance of Proderm Technology TM. Unlike some creamsand lotions which have a tendency to leave the skin feeling greasy afterapplication, Neosalus, a water-lipid based foam, absorbs quickly, spreadseasily, and is non-greasy. Patients can resume their work and daily activitiesimmediately after applying Neosalus, thus enhancing compliance and maximizingtreatment results. Quinnova Pharmaceuticals sales force calls on dermatologists across the UnitedStates. About Quinnova Pharmaceuticals, Inc.Quinnova Pharmaceuticals, Inc.

is a specialty pharmaceutical company focused onthe development and commercialization of prescription drug products based oninnovative topical drug delivery platforms For more information, please visit Quinnova Pharmaceuticals, Inc., NewtownJana Wang, Copyright Business Wire 2009. - 55 Reduction in Staff Since Start of Q4 2008- Evaluation of strategic alternatives on-going- Executive VP Steps Down and Resumes Board RoleSAN DIEGO, Jan. 5 /PRNewswire-FirstCall/ ADVENTRX Pharmaceuticals, Inc.(NYSE Alternext US: ANX) announced today that it has implemented a furtherreduction-in-force in an effort to extend its remaining cash and to prepareitself for a strategic transaction.This follows a reduction implemented inOctober 2008.In all, the Company's workforce has declined by approximately55 since the beginning of the fourth quarter of 2008.Following the currentreduction and other planned departures, the Company will have fourteenemployees.In addition, the Company has substantially reduced or delayedspending on third-party consulting and vendor services, including contractmanufacturing.ADVENTRX's remaining employees will focus their efforts on continuing toevaluate strategic options, as well as continuing the Company's on-goingbioequivalence study of ANX-514 (docetaxel emulsion) and activities related tosubmitting a New Drug Application for ANX-530 (vinorelbine emulsion).Thecost-cutting measures announced today should not have a direct and immediateeffect on the Company's previously announced timelines.However, any furthercost-reductions or expense reductions/delays likely will have a negativeimpact the Company's development and commercialization plans.As part of its overall cost-cutting measures, Mark N K. Bagnall, who in April2008 joined the Company as Executive Vice President and Chief FinancialOfficer, agreed to return to his prior role as solely a member of theCompany's Board of Directors, and has agreed to provide consulting services onan as-needed basis."It's never easy to let go employees, particularly those who have been withthe Company for many years and who have made contributions to the Company.